Screener Summaries Updates Institutions Sign In More Updates › Leadership & Pay › CVKD Leadership & Pay · Jul 10, 2026
James J. Ferguson III will resign as Chief Medical Officer of Cadrenal Therapeutics, Inc. effective July 31, 2026 CVKD Cadrenal Therapeutics, Inc.
James J. Ferguson III will resign as Chief Medical Officer of Cadrenal Therapeutics, Inc. effective July 31, 2026. The company is searching for a replacement and negotiating separation terms. Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic solutions for patients with complex medical needs.
More from Cadrenal Therapeutics, Inc. Cadrenal Therapeutics initiates formal strategic process to maximize value of its asset portfolio Oct 7, 2026 On August 31, 2026, Cadrenal Therapeutics announced positive feedback from a July 28 FDA Type D meeting regarding the… Aug 31, 2026 Cadrenal Therapeutics reported second quarter 2026 financial results and provided a corporate update Aug 13, 2026 Cadrenal Therapeutics, Inc. announced a strategic realignment of its clinical portfolio into a Cardiac Acute Critical… Jul 21, 2026 Cadrenal Therapeutics, Inc. entered into a separation agreement with Chief Medical Officer James J. Ferguson III, who… Jul 17, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
